Combination immunotherapy as second or third line treatment of mesothelioma shows promising results – News-Medical.net
|
Combination immunotherapy as second or third line treatment of mesothelioma shows promising results
News-Medical.net Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 … |
